Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
AMBIT BIOSCIENCES CORP (AMBI) Create: Alert

All | News | Filings
Date FiledTypeDescription
12/10/2014 SC 13G/A Senrigan Capital Management Ltd reports a 0% stake in Ambit Biosciences Corp
11/19/2014 SC 13D/A PERSEUS SOROS BIOPHARMACEUTICAL FUND LP reports a 0% stake in Ambit Biosciences Corporation
11/17/2014 8-K Quarterly results
11/12/2014 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
10/28/2014 SC TO-T/A Form SC TO-T/A - Tender offer statement by Third Party: [Amend]
10/24/2014 SC 13G Senrigan Capital Management Ltd reports a 5.5% stake in Ambit Biosciences Corp
09/29/2014 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits
Docs: "Agreement and Plan of Merger, by and among Ambit Biosciences Corporation, Daiichi Sankyo Company, Limited and Charge Acquisition Corp",
"Form of Tender Agreement, by and among Daiichi Sankyo Company, Limited, Charge Acquisition Corp. and the directors and certain stockholders of Ambit Biosciences Corporation",
"Form of Contingent Value Rights Agreement"
09/04/2014 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
Docs: "Amendment to Amended and Restated Bylaws of Ambit Biosciences Corporation"
08/26/2014 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]
08/12/2014 10-Q Quarterly Report for the period ended June 30, 2014
08/12/2014 8-K Quarterly results
Docs: "AMBIT BIOSCIENCES ANNOUNCES SECOND QUARTER 2014 OPERATING RESULTS SAN DIEGO — August 12, 2014 — Ambit Biosciences , a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced operating results for the second quarter 2014. The company will host a conference call today to discuss financial results for the quarter and to provide an operational update for the first half of 2014. “We are pleased to have initiated our QUANTUM-R Phase 3 trial, our most notable achievement of the first half,” said Michael Martino, Ambit's President and Chief Executive Officer. “The trial is progressing and sites continue to be activated on plan. This will remain our primary operating focus throughout the year. We..."
08/08/2014 10-K/A Annual Report for the period ended December 31, 2013 [amend]
06/04/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
05/19/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement, under the Company's 2014 Long Term Incentive Program"
05/06/2014 10-Q Quarterly Report for the period ended March 31, 2014
05/06/2014 8-K Quarterly results
Docs: "AMBIT BIOSCIENCES ANNOUNCES FIRST QUARTER 2014 OPERATING RESULTS"
04/09/2014 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/20/2014 10-K Annual Report for the period ended December 31, 2013
03/20/2014 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits
Docs: "AMBIT BIOSCIENCES ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2013 OPERATING RESULTS"
01/27/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
01/10/2014 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/03/2013 8-K Form 8-K - Current report
11/07/2013 10-Q Quarterly Report for the period ended September 30, 2013
11/07/2013 8-K Quarterly results
Docs: "AMBIT BIOSCIENCES ANNOUNCES THIRD QUARTER 2013 OPERATING RESULTS"
09/11/2013 SC 13D/A GrowthWorks Canadian Fund Ltd. reports a 6.3% stake in Ambit Biosciences Corporation
08/13/2013 10-Q Quarterly Report for the period ended June 30, 2013
08/13/2013 8-K Quarterly results
Docs: "Ambit Biosciences Corporation Announces Second Quarter 2013 Operational Results - Company to Host Conference Call and Webcast at 5:00 p.m. EDT, Today, August 13, 2013 SAN DIEGO - August 13, 2013 - Ambit Biosciences , a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced results for the second quarter and six months ended June 30, 2013. The company will host a conference call today to provide an operational update and discuss financial results, its first as a public company. “The second quarter was transformative for Ambit. We successfully completed our initial public offering, which put us on solid financial footing to continue the clinical development of quizartinib, our lead drug c..."
07/22/2013 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/24/2013 SC 13G Foresite Capital Fund I, L.P. reports a 11.7% stake in Ambit Biosciences Corporation
05/30/2013 SC 13D AMBIT BIOSCIENCES CORP reports a 11.6% stake in AMBIT BIOSCIENCES CORPORATION
05/28/2013 SC 13G Form SC 13G - Statement of acquisition of beneficial ownership by individuals
05/15/2013 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend]
05/02/2013 S-1/A Form S-1/A - General form for registration of securities under the Securities Act of 1933 [Amend]
03/28/2013 S-1/A Form S-1 - General form for registration of securities under the Securities Act of 1933 [amend]
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy